LEGAL PROCEEDINGS
−Removed: A number of actions have been
−Removed: commenced against us in the ordinary course of business by vendors, landlords and former landlords, including a third party claim as a
−Removed: result of an injury suffered on a portion of a leased property not occupied by us.
−Removed: As certain of these claims represent amounts included
−Removed: in accounts payable they are not specifically discussed herein.
On October 2, 2018, Contract
8 unchanged sentences
for summary judgement.
−Removed: In the Order, the court granted Contract Pharmacal’s Motions to drop its claim for specific performance
−Removed: and to amend its Complaint to reduce its claim for damages to $700,000.
−Removed: Contract Pharmacal filed a Motion to reargue which the Court
−Removed: denied on November 30, 2021.
−Removed: On March 10, 2022, Contract Pharmacal filed an appeal to the Court’s decision with the Appellate Division
−Removed: which we will oppose.
−Removed: We dispute the validity of the claims asserted by Contract Pharmacal, continue to believe we have a meritorious
−Removed: defense to those claims and intend to dispute the validity of the claim asserted by Contract Pharmacal.
−Removed: From time to time we may be
−Removed: engaged in various lawsuits and legal proceedings in the ordinary course of our business.
−Removed: We are currently not aware of any legal proceedings
−Removed: the ultimate outcome of which, in our judgment based on information currently available, would have a material adverse effect on our business,
−Removed: financial condition or operating results.
−Removed: There are no proceedings in which any of our directors, officers or affiliates, or any registered
−Removed: or beneficial stockholder of our common stock, is an adverse party or has a material interest adverse to our interest.
+Added: In the Order, the court granted Contract Pharmacal’s Motions to drop its claim for specific performance and
+Added: to amend its Complaint to reduce its claim for damages to $700,000.
+Added: Subsequently, Contract Phamacal moved to amend its Complaint.
+Added: and the Court denied the request to amend the Complaint.
+Added: Contract Pharmacal filed a Motion to reargue which the Court denied on November
+Added: On March 10, 2022, Contract Pharmacal filed an appeal to the Court’s decision with the Appellate Division which we have
+Added: We dispute the validity of the claims asserted by Contract Pharmacal, continue to believe we have a meritorious defense to those
+Added: claims and intend to dispute the validity of the claim asserted by Contract Pharmacal.
+Added: time to time we may be engaged in various lawsuits and legal proceedings in the ordinary course of our business.
+Added: We are currently not
+Added: aware of any legal proceedings the ultimate outcome of which, in our judgment based on information currently available, would have a
+Added: material adverse effect on our business, financial condition or operating results.
+Added: There are no proceedings in which any of our directors,
+Added: officers or affiliates, or any registered or beneficial stockholder of our common stock, is an adverse party or has a material interest
+Added: adverse to our interest.
MINE SAFETY DISCLOSURES
−Removed: Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.